Drug pricing

News

CMS has revealed a new, voluntary access programme that aims to broaden the use of GLP-1 agonist medicines for diabetes and obesity.

News

CMS unveils two more programmes in the Trump administration's efforts to cut drug prices, which have not been well received by the pharma industry.

News

The UK has cut its voluntary rebate rate for new medicines supplied to the NHS to 14.5% next year, but industry says this is "only the first step."

News

A deal between the UK and the US will maintain tariffs on imports into the US at 0%, but prices of medicines used by the NHS will go up.

News

The CMS has revealed the prices for the second batch of 15 drugs going through Medicare's negotiation process, promising net savings of 44% on 2024.

News

The pricing agreement between Novo Nordisk and Eli Lilly and the Trump administration on GLP-1 drugs for diabetes and obesity has arrived.